"Self-Compassion and Self-Efficacy in Parkinson's Disease: Associations With Symptoms, Function, and Quality of Life"

NCT07488351 | Not Yet Recruiting

• 1 other identifier: 2026-03-130
• Study Type: observational
• Target: 100
• Locations: 0 countries
• Sites: N/A

Brief Summary

The aim of this study is to evaluate the associations of self-compassion and self-efficacy levels with symptom severity, functional status, and quality of life in individuals with Parkinson's disease.

Conditions

Parkinson Disease, Symptom Severity, Functional Status, Quality of Life, Self-compassion, and Self-efficacy

Outcome Measures

Primary Outcomes (3)

• Self-Compassion Scale (SCS) Total Score

  Self-compassion will be measured using the Self-Compassion Scale (SCS), a validated self-report instrument assessing multiple dimensions of self-compassion. The total score will be calculated, with higher scores indicating greater self-compassion.

  Baseline (at the time of questionnaire completion)

• Self-Efficacy for Managing Chronic Disease 6-Item Scale Total Score

  Self-efficacy will be measured using the Self-Efficacy for Managing Chronic Disease 6-Item Scale, a validated self-report measure. The total score will be calculated, with higher scores indicating greater perceived self-efficacy.

  Baseline (at the time of questionnaire completion)

• Unified Parkinson's Disease Rating Scale (UPDRS) Total Score

  Symptom severity will be measured using the Unified Parkinson's Disease Rating Scale (UPDRS), a validated clinician-rated instrument assessing motor and non-motor symptoms. Higher total scores indicate greater disease severity.

  Baseline (at the time of questionnaire completion)

Secondary Outcomes (4)

• Timed Up and Go (TUG) Test Completion Time in Seconds

  Baseline (at the time of questionnaire completion)

• Six-Minute Walk Test (6MWT) Distance in Meters

  Baseline (at the time of questionnaire completion)

• Mini-Balance Evaluation Systems Test (Mini-BESTest) Total Score

  Baseline (at the time of questionnaire completion)

• Parkinson's Disease Questionnaire-39 (PDQ-39) Total Score

  Baseline (at the time of questionnaire completion)

Interventions

Self-Report Questionnaire Assessment OTHER

This study does not involve any therapeutic intervention. Participants will complete a set of self-report questionnaires assessing self-compassion, self-efficacy, symptom severity, functional status, and quality of life. Data will be collected in a single session for observational analysis.

Eligibility Criteria

• Age: 40 Years - 85 Years
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The study population will consist of individuals diagnosed with Parkinson's disease who are classified as Hoehn and Yahr stage 1-3, aged between 40 and 85 years, and have sufficient cognitive function (MMSE ≥ 24). Participants will be recruited from patients attending the Movement Disorders Outpatient Clinic of the Neurology Department

You may qualify if:

• Clinically diagnosed Parkinson's disease
• Hoehn and Yahr stage 1-3
• Age between 40 and 85 years
• Sufficient cognitive function to communicate (Mini-Mental State Examination \[MMSE\] score ≥ 24)
• Patients attending the Movement Disorders Outpatient Clinic of the Neurology Department
• Willingness to participate and provide informed consent

You may not qualify if:

• Presence of psychiatric disorders (e.g., major depression, psychotic disorders)
• Diagnosis of advanced dementia
• Presence of uncontrolled systemic chronic diseases (e.g., diabetes mellitus, hypertension) or severe cardiovascular or respiratory conditions
• Presence of additional orthopedic or neurological conditions that may affect test performance
• Severe visual or hearing impairments that could interfere with assessments
• Inability to cooperate adequately with the physiotherapist during assessments

Sponsors & Collaborators

• Acibadem University: lead

MeSH Terms

Conditions

Parkinson Disease

Condition Hierarchy (Ancestors)

Parkinsonian Disorders; Basal Ganglia Diseases; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Movement Disorders; Synucleinopathies; Neurodegenerative Diseases

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: CROSS SECTIONAL
• Target Duration: 1 Day
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 18, 2026
• First Posted: March 23, 2026
• Study Start: March 30, 2026
• Primary Completion (Estimated): December 30, 2026
• Study Completion (Estimated): March 30, 2027
• Last Updated: March 23, 2026

Record last verified: 2026-03